Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

Organic molecular crystals can respond to external stimuli such as heat, light, and mechanical force, making them attractive candidates for next-generation functional materials. However, predicting ...

Bupropion conferred modest reductions in cancer-related fatigue compared with placebo, according to results of a randomized ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present ...

(NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line ...

Aging is accompanied by progressive changes in brain structure and function that may affect cognition, emotional regulation, and adaptive behavior. While ...

Abstract: A novel weighed and summing bipolar photonic digital-to-analog converter (BPDAC) scheme employing optical differential phase shift keying modulation and balanced detection is proposed and ...

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...

Sjögren’s disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine ...